US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SNDK $1,704.16 ▲+0.00% SDEV $3.94 ▲+0.00% AMD $631.75 ▲+0.00% SKHY $195.02 ▲+0.00% TSLA $378.73 ▲+0.00%
FinancialContent

Alamar Biosciences, Inc. - Class A common stock (NQ:ALMR)

38.13 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alamar Biosciences, Inc. - Class A common stock

News headline image
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer 
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab 
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging | Highly sensitive... 
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting... 
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences Reports First Quarter 2026 Financial Results
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
From Alamar Biosciences, Inc.
Via GlobeNewswire